%0 Journal Article
%T Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
%A Carlos Henrique dos Anjos
%A Gustavo Duarte Ramos Matos
%A Marcos Segura
%A Tatiana Strava Corr¨ºa
%J Archive of "Case Reports in Oncology".
%D 2018
%R 10.1159/000488669
%X Patients with salivary duct cancer (SDC) and HER2 overexpression could receive trastuzumab in combination with chemotherapy for metastatic disease. No standard treatment exists for patients with HER2-positive metastatic SDC after progression. We report an excellent patient response to second-line treatment with T-DM1 after progression on paclitaxel plus trastuzumab
%K Trastuzumab emtansine
%K Salivary gland tumor
%K HER2 positivity
%K Second line
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981674/